I think NAN may drift here a bit without any news for a while. For me I am confident the NHS are coming on board but the revenue will take a while to flow and market is much smaller than the US. The US market seems to be going well.
2 catalysts that will see a re rating is signs of inroads into a non anglo market ie Japan and the announcement of their new product even though that may take a while to get through the FDA etc.
I have no idea how receptive the Japanese market will be the trophon. At first glance I would have thought the concept would be very attractive but there may be other barriers such as funding, bias against non japanese tech etc.
Catalysts
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NAN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.99 |
Change
0.040(1.36%) |
Mkt cap ! $905.9M | |||
| Open | High | Low | Value | Volume |
| $2.98 | $3.04 | $2.96 | $3.563M | 1.185M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 18897 | $2.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.01 | 7344 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NAN (ASX) Chart |